Hyaline fibromatosis syndrome with mutation c.1074delT of the CMG2 gene: a case report

Journal of Medical Case Reports

Abdelaziz Sefiani²  Aicha Hajjioui¹  Soukaina Guaoua²  Imane Cherkaoui Jaouad² 

[1] Centre de pédiatrie, 21, av. 10 Mai, Tétouan, Morocco;Département de Génétique Médicale, Institut National d'Hygiène, Av. Ibn Batouta, BP 769, CP 11400 Rabat, Morocco

关键词: Hyaline fibromatosis syndrome;    Infantile systemic hyalinosis;    CMG2;   

Others  :  1181061
DOI  :  10.1186/1752-1947-8-291

 received in 2014-02-22, accepted in 2014-07-12,  发布年份 2014

【 摘 要 】

Introduction

Juvenile hyaline fibromatosis and infantile systemic hyalinosis are variants of the same autosomal recessive syndrome; hyaline fibromatosis syndrome, characterized by papulonodular skin lesions, gingival hypertrophy, flexion contractures of joints, osteolytic bone lesions and stunted growth. Infantile systemic hyalinosis is distinguished from juvenile hyaline fibromatosis by its more severe phenotype, which includes hyaline deposits in multiple organs, recurrent infections and death within the first two years of life.

Hyaline fibromatosis syndrome is due to mutations of the gene-encoding capillary morphogenesis protein 2 (CMG2). Cases have been reported in different countries but to the best of our knowledge, this is the first reported Moroccan patient with hyaline fibromatosis syndrome and carrying the CMG2 mutation.

Case presentation

We report the case of an eight-year-old Moroccan male patient with typical features of hyaline fibromatosis syndrome: multiple recurring subcutaneous tumors, gingival hypertrophy, joint contractures and other anomalies carrying a homozygous mutation in the CMG2 gene. The identification of the mutation in our patient allowed us to do a presymptomatic diagnosis in our patient’s sister, a two-day-old newborn, who is carrying the familial mutation in the heterozygous state. Early recognition of this condition is important for genetic counseling and early treatment.

Conclusions

Hyaline fibromatosis syndrome might be underdiagnosed. Molecular diagnosis will help clinicians and geneticists, firstly to conduct genetic counseling, prenatal diagnosis and early treatment, and secondly to gain better understanding of the disease and genotype-phenotype correlations.

【 授权许可】

   
2014 Cherkaoui Jaouad et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

【 参考文献 】

• [1]Mayer-da-Silva A, Poiares-Baptista A, Guerra Rodrigo F, Teresa-Lopes M: Juvenile hyaline fibromatosis. A histologic and histochemical study. Arch Pathol Lab Med 1988, 112:928-931.
• [2]Stucki U, Spycher MA, Eich G, Rossi A, Sacher P, Steinmann B, Superti-Furga A: Infantile systemic hyalinosis in siblings: clinical report, biochemical and ultrastructural findings, and review of the literature. Am J Med Genet 2001, 100:122-129.
• [3]Hanks S, Adams S, Douglas J, Arbour L, Atherton DJ, Balci S, Bode H, Campbell ME, Feingold M, Keser G, Kleijer W, Mancini G, McGrath JA, Muntoni F, Nanda A, Teare MD, Warman M, Pope FM, Superti-Furga A, Futreal PA, Rahman N: Mutations in the gene encoding capillary morphogenesis protein 2 cause juvenile hyaline fibromatosis and infantile systemic hyalinosis. Am J Hum Genet 2003, 73:791-800.
• [4]El-Kamah GY, Fong K, El-Ruby M, Afifi HH, Clements SE, Lai-Cheong JE, Amr K, El-Darouti M, McGrath JA: Spectrum of mutations in the ANTXR2 (CMG2) gene in infantile systemic hyalinosis and juvenile hyaline fibromatosis. Br J Dermatol 2010, 163:213-215.
• [5]Nofal A, Sanad M, Assaf M, Nofal E, Nassar A, Almokadem S, Attwa E, Elmosalamy K: Juvenile hyaline fibromatosis and infantile systemic hyalinosis: a unifying term and a proposed grading system. J Am Acad Dermatol 2009, 61:695-700.
• [6]Whitfield A, Robinson AH: A further report on the remarkable series of cases of molluscum fibrosum in children communicated to the Society by Dr. John Murray in 1873. Med Chir Trans 1903, 86:293-302.
• [7]Drescher E, Woyke S, Markiewicz C, Tegi S: Juvenile fibromatosis in siblings (fibromatosis hyalinica multiplex juvenilis). J Pediat Surg 1967, 2:427-430.
• [8]Landing BH, Nadorra R: Infantile systemic hyalinosis: report of four cases of a disease, fatal in infancy, apparently different from juvenile systemic hyalinosis. Pediatr Pathol 1986, 6:55-79.
• [9]Al-Mayouf SM, AlMehaidib A, Bahabri S, Shabib S, Sakati N, Teebi AS: Infantile systemic hyalinosis: a fatal disorder commonly diagnosed among Arabs. Clin Exp Rheumatol 2005, 23:717-720.
• [10]Al-Mubarak L, Al-Makadma A, Al-Khenaizan S: Infantile systemic hyalinosis presenting as intractable infantile diarrhea. Eur J Pediatr 2009, 168:363-365.
• [11]Scobie HM, Rainey GJ, Bradley KA, Young JA: Human capillary morphogenesis protein 2 functions as an anthrax toxin receptor. Proc Natl Acad Sci U S A 2003, 100:5170-5174.
• [12]Liu S, Crown D, Miller-Randolph S, Moayeri M, Wang H, Hu H, Morley T, Leppla SH: Capillary morphogenesis protein-2 is the major receptor mediating lethality of anthrax toxin in vivo. Proc Natl Acad Sci U S A 2009, 106:12424-12429.
• [13]Reeves CV, Dufraine J, Young JA, Kitajewski J: Anthrax toxin receptor 2 is expressed in murine and tumor vasculature and functions in endothelial proliferation and morphogenesis. Oncogene 2009, 29:789-801.
• [14]Deuquet J, Lausch E, Guex N, Abrami L, Salvi S, Lakkaraju A, Ramirez MC, Martignetti JA, Rokicki D, Bonafe L, Superti-Furga A, van der Goot FG: Hyaline fibromatosis syndrome inducing mutations in the ectodomain of anthrax toxin receptor 2 can be rescued by proteasome inhibitors. EMBO Mol Med 2011, 3:208-221.
• [15]Abrami L, Leppla SH, van der Goot FG: Receptor palmitoylation and ubiquitination regulate anthrax toxin endocytosis. J Cell Biol 2006, 172:309-320.
• [16]Abrami L, Kunz B, van der Goot FG: Anthrax toxin triggers the activation of src-like kinases to mediate its own uptake. Proc Natl Acad Sci U S A 2010, 107:1420-1424.
• [17]Yan SE, Lemmin T, Salvi S, Lausch E, Superti-Furga A, Rokicki D, Dal Peraro M, van der Goot FG: In-depth analysis of hyaline fibromatosis syndrome frameshift mutations at the same site reveal the necessity of personalized therapy. Hum Mutat 2013, 34:1005-1017.
• [18]Rebbapragada I, Lykke-Andersen J: Execution of nonsense-mediated mRNA decay: what defines a substrate? Curr Opin Cell Biol 2009, 21:394-402.
• [19]Jaouad IC, Elalaoui SC, Sbiti A, Elkerch F, Belmahi L, Sefiani A: Consanguineous marriages in Morocco and the consequence for the incidence of autosomal recessive disorders. J Biosoc Sci 2009, 41:575-581.